Momentum Bioscience
1
12M
1
0.06
- Areas of investment
Summary
Momentum Bioscience appeared to be the Corporate Investor, which was created in 2005. The main office of represented Corporate Investor is situated in the Reading. The fund was located in Europe if to be more exact in United Kingdom.
The standard case for the fund is to invest in rounds with 3 partakers. The meaningful sponsors for the fund in investment in the same round are Novartis Venture Fund, Cycad Group. In the next rounds fund is usually obtained by Nextech Invest, Cycad Group, Parker Institute for Cancer Immunotherapy.
Among the various public portfolio startups of the fund, we may underline ImaginAb For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular fund investment industries, there are Biotechnology, Clinical Trials.
The fund is constantly included in less than 2 investment rounds annually. The common things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2012.
The fund was created by Bill Mullen.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.06
- Investments by industry
- Biotechnology (1)
- Clinical Trials (1)
- Health Care (1)
- Health Diagnostics (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2012
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 14
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| ImaginAb | 27 Mar 2012 | Biotechnology, Health Care, Health Diagnostics, Clinical Trials | Early Stage Venture | 12M | United States, California, Inglewood |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.